Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
There, the business plans to submit an IND application for a Phase I/II in the second half of 2023, with a readout in 2024. Competition in an increasingly heated market. Vaxcyte’s recent clinical success brings further competition into a sector, which is becoming increasingly heated.
Let's personalize your content